FGF23 and chronic kidney disease: In the present study, we firstly investigated the changes in serum and intracardiac FGF23 levels and RAAS parameters in the early stage of LVH progression, and secondly assessed the influences of FGF23 and RAAS blockade on their changes and LVH, using a pressure-overload induced LVH model mouse without CKD.